In a major policy push aimed at addressing the nation’s mental health crisis, Donald Trump recently signed an executive order to fundamentally transform how the Food and Drug Administration (FDA) handles psychedelic-based treatments. This directive specifically orders the FDA to expedite its review of drugs categorized as breakthrough therapies, with a particular focus on helping veterans struggling with treatment-resistant conditions. Trump described the signing as a historic moment for medical research, emphasizing that these experimental treatments are in advanced clinical trial stages to confirm their safety and efficacy for the public.
A core element of this medical reform is the prioritization of ibogaine, a naturally occurring psychedelic substance. Trump cited a 2024 Stanford University study which revealed that special operations veterans suffering from traumatic brain injuries experienced a staggering 80% to 90% reduction in symptoms of depression and anxiety within just one month of treatment. To support this scientific frontier, the federal government has committed a $50 million research investment, matching a similar funding commitment from the state of Texas. The order also leverages the Right to Try law, ensuring that desperately ill patients can access these treatments before they receive full regulatory approval, thereby clearing traditional bureaucratic hurdles.
Beyond the medical sector, the order mandates increased cooperation between the FDA and the Department of Veterans Affairs to facilitate the fast rescheduling of psychedelics once they pass the necessary safety benchmarks. Trump criticized previous administrative delays, noting that while research has existed for years, meaningful legislative action had been absent. By streamlining data sharing and reducing red tape, the administration aims to provide a lifeline to cherished veterans and others suffering from debilitating mental illnesses, helping them to reclaim their lives and overall well-being.
Parallel to these healthcare advancements, Trump previously issued a sweeping directive titled “Ensuring Citizenship Verification and Integrity in Federal Elections.” This executive order is designed to tighten federal oversight of the voting process by expanding the verification of voter eligibility. It establishes a framework for the Department of Homeland Security (DHS) and the Social Security Administration (SSA) to collaborate on the creation of State Citizenship Lists. These lists, compiled from federal databases, are intended to help state election officials verify that only U.S. citizens are participating in federal elections, though the order clarifies that state laws still govern final registration procedures.
The election integrity directive also grants new responsibilities to the Department of Justice (DOJ) and the U.S. Postal Service (USPS). The DOJ has been instructed to prioritize the investigation and prosecution of election law violations, specifically targeting those involved in distributing ballots to ineligible individuals. Meanwhile, the Postmaster General is required to develop a standardized national system for tracking mail-in and absentee ballots within 60 days. This involves the use of unique tracking barcodes and specifically designated official election mail envelopes to ensure all ballots are processed securely through automated systems, reflecting a broader commitment to electoral transparency and security.
